Globus Medical (GMED)
(Delayed Data from NYSE)
$73.43 USD
+0.80 (1.10%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $73.40 -0.03 (-0.04%) 6:32 PM ET
1-Strong Buy of 5 1
C Value B Growth D Momentum C VGM
Globus Medical (GMED) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Downside to Average Price Target |
---|---|---|---|
$72.08 | $85.00 | $55.00 | -0.76% |
Price Target
Based on short-term price targets offered by 13 analysts, the average price target for Globus Medical comes to $72.08. The forecasts range from a low of $55.00 to a high of $85.00. The average price target represents a decline of 0.76% from the last closing price of $72.63.
Analyst Price Targets (13)
Broker Rating
Globus Medical currently has an average brokerage recommendation (ABR) of 2.07 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 15 brokerage firms. The current ABR compares to an ABR of 2.07 a month ago based on 15 recommendations.
Of the 15 recommendations deriving the current ABR, seven are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 46.67% and 6.67% of all recommendations. A month ago, Strong Buy made up 46.67%, while Buy represented 6.67%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 7 | 7 | 7 | 7 | 6 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 6 | 6 | 6 | 6 | 7 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.07 | 2.07 | 2.07 | 2.07 | 2.20 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/16/2024 | Truist Securities | Richard Newitter | Hold | Hold |
7/15/2024 | BTIG | Ryan Zimmerman | Strong Buy | Strong Buy |
5/20/2024 | Piper Sandler | Matthew O'Brien | Hold | Strong Buy |
5/9/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/8/2024 | Needham & Company | David Saxon | Hold | Hold |
5/8/2024 | Roth Capital Partners | Jason Wittes | Strong Buy | Strong Buy |
5/8/2024 | Wells Fargo Securities | Vikramjeet S Chopra | Hold | Hold |
5/8/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/17/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
3/15/2024 | JMP Securities | David L Turkaly | Hold | Hold |
12/20/2023 | Canaccord Genuity | William J Plovanic | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.07 |
ABR (Last week) | 2.07 |
# of Recs in ABR | 15 |
Average Target Price | $72.08 |
LT Growth Rate | 12.70% |
Industry | Medical - Instruments |
Industry Rank by ABR | 143 of 252 |
Current Quarter EPS Est: | 0.68 |